CGTX — Cognition Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $76.05m
- $46.13m
Annual cashflow statement for Cognition Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.84 | -7.84 | -11.7 | -21.4 | -25.8 |
| Depreciation | |||||
| Non-Cash Items | 1.09 | 1.24 | 5.15 | 3.72 | 4.83 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.57 | 3.07 | 2.84 | -0.943 | 4.85 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.1 | -3.43 | -3.63 | -18.5 | -16 |
| Capital Expenditures | -0.144 | -0.01 | -0.027 | -0.171 | -0.147 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.144 | -0.01 | -0.027 | -0.171 | -0.147 |
| Financing Cash Flow Items | -0.034 | -0.093 | 8.94 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.79 | 5.76 | 53.2 | 5.55 | 4.52 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.508 | 2.3 | 49.5 | -13.2 | -11.6 |